Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

Arsenal have a history of recruiting Dutch players, both in the past and in the present. Within the current squad, Jurrien ...

What's in the stars today: The provided horoscopes do not specifically address the astrological implications of having the ...

Researchers discovered that clogged brain “drains” show up early in people at risk of Alzheimer’s disease. These blockages, ...

Premature infants (delivery before 37 wk of gestation) admitted to the NICU at the University of Iowa Children's Hospital between 2000 and 2009 were recruited to examine preterm birth (PTB) and ...

Palantir Technologies Inc is turning a long running Silicon Valley debate into corporate policy, with Chief Executive Officer ...

UK Biobank analysis found cancer diagnosis raised cardiovascular disease mortality by 50%, with proteomic signals in ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Life Extension reports on 15 science-backed longevity supplements to enhance lifespan and health, emphasizing the importance ...